Amarin Corp Plc (AMRN)

[AtlasSnuggled]

same article, Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio.

Abstract showing up in Pub Med, US National Library of Medicine National Institutes of Health,

verifying in prepublication now, slated to come in
J Atheroscler Thromb. 2013 Sep 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/24047614

better than watermark on a pdf , I'd say

Conclusion
Dyerberg and colleagues examined the relationship between EPA and CVD, and the JELIS study recently demonstrated that EPA administration reduces the risk of CVD. An important difference between EPA and DHA is the metabolism of EPA to bioactive PGI3. It is assumed that, similar to PGI2, PGI3 inhibits platelet aggregation, vascular contraction, myocardial ischemic injury and arteriosclerosis and induces neoangiogenesis.

Therefore, it is speculated that the CVD risk reduction induced by EPA is also associated with the effects of PGI3 in addition to the numerous effects of EPA itself (such as TG reduction, inflammation inhibition and improvements in plasma membrane fluidity).

This hypothesis is confirmed by the following findings: an increased CVD risk was found to be associated with a reduction in the EPA/AA ratio, and the EPA/AA ratio was found to be positively correlated with the (PGI2+PGI3)/TXA2 ratio.